Human papillomavirus and control of cervical cancer in India

Expert Review of Obstetrics and Gynecology

Volumn 5, Issue 3, 2010, Pages 329-346

  Bharti, Alok C ^a   Shukla, Shirish ^a   Mahata, Sutapa ^a   Hedau, Suresh ^a   Das, Bhudev C ^a,b  

^a INSTITUTE OF CYTOLOGY AND PREVENTIVE ONCOLOGY   (India)

^b UNIVERSITY OF DELHI   (India)

Author keywords

Cancer control; Cervical cancer; Early diagnosis; HPV vaccine; Human papillomavirus; Prevention screening

Indexed keywords

BERBERINE; CURCUMIN; HERBACEOUS AGENT; PRANEEM; UNCLASSIFIED DRUG; WART VIRUS VACCINE;

CANCER CONTROL; CANCER MORTALITY; CANCER SCREENING; CARCINOGENESIS; CYTOLOGY; DNA DETERMINATION; DRUG EFFICACY; DRUG MONITORING; HEALTH PROGRAM; HUMAN; INDIA; NONHUMAN; PAPILLOMAVIRUS INFECTION; PREVALENCE; PRIMARY PREVENTION; REVIEW; RISK FACTOR; SECONDARY PREVENTION; UTERINE CERVIX CANCER; VACCINATION; VIRUS DETECTION; VIRUS TRANSMISSION; WART VIRUS; WORLD HEALTH ORGANIZATION;

EID: 77952115255     PISSN: 17474108     EISSN: None     Source Type: Journal    
DOI: 10.1586/eog.10.23     Document Type: Review

References (92)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J. Clin. 55(2), 74-108 (2005).
2. Sankaranarayanan R. Overview of cervical cancer in the developing world. FIGO 6th Annual Report on the Results of Treatment in Gynecological Cancer. Int. J. Gynaecol. Obstet. 95(Suppl. 1), S205-S210 (2006). (Pubitemid 44856728)
3. Sankaranarayanan R, Ferlay J. Worldwide burden of gynaecological cancer: the size of the problem. Best Pract. Res. Clin. Obstet. Gynaecol. 20(2), 207-225 (2006). (Pubitemid 43380597)
4. Franceschi S. The IARC commitment to cancer prevention: the example of papillomavirus and cervical cancer. Recent Results Cancer Res. 166, 277-297 (2005).
5. Cancer Incidence in Five Continents (Volume VIII). Parkin DM, Whelan SL, Ferlay J, Teppo L, Thomas DB (Eds). International Agency for Research on Cancer, Lyon, France (2002).
6. Human Papillomaviruses. IARC (Ed.) International Agency for Research on Cancer, Lyon, France (2005).
7. Das BC, Gopalkrishna V, Hedau S, Katiyar S. Cancer of the uterine cervix and human papillomavirus infection. Curr. Sci. 78(1), 52-63 (2000).
8. Pagliusi S. Vaccines against human papillomavirus. WHO, Geneva, Switzerland (2001).
9. Partridge JM, Koutsky LA. Genital human papillomavirus infection in men. Lancet Infect. Dis. 6(1), 21-31 (2006). (Pubitemid 41831374)
10. Stanley M. Chapter 17: genital human papillomavirus infections - current and prospective therapies. J. Natl Cancer Inst. Monogr. 31, 117-124 (2003).
11. Munger K, Phelps WC, Bubb V, Howley PM, Schlegel R. The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes. J. Virol. 63(10), 4417-4421 (1989). (Pubitemid 19229441)
12. Noller KL. Incident and demographic trends in cervical neoplasia. Am. J. Obstet. Gynecol. 175(4 Pt 2), 1088-1090 (1996).
13. Zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat. Rev. Cancer 2(5), 342-350 (2002). (Pubitemid 37328947)
14. Jo H, Kim W. Implications of HPV infection in uterine cervical cancer. Cancer Ther. 3, 419-434 (2005).
15. Ley C, Bauer HM, Reingold A et al. Determinants of genital human papillomavirus infection in young women. J. Natl Cancer Inst. 83(14), 997-1003 (1991).
16. Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. N. Engl. J. Med. 338(7), 423-428 (1998). (Pubitemid 28135669)
17. Richardson H, Kelsall G, Tellier P et al. The natural history of type-specific human papillomavirus infections in female university students. Cancer Epidemiol. Biomarkers Prev. 12(6), 485-490 (2003). (Pubitemid 36713640)
18. Agarwal SK, Chatterji A, Bhambhani S, Sharma BK. Immunohistochemical co-expression of human papillomavirus type 16/18 transforming (E6) oncoprotein and p53 tumour suppressor gene proteins in oesophageal cancer. Indian J. Exp. Biol. 36(6), 559-563 (1998). (Pubitemid 128468945)
19. Koutsky L. Epidemiology of genital human papillomavirus infection. Am. J. Med. 102(5A), 3-8 (1997). (Pubitemid 127695953)
20. Das BC, Hussain S, Nasare V, Bharadwaj M. Prospects and prejudices of human papillomavirus vaccines in India. Vaccine 26(22), 2669-2679 (2008).
21. Ho GY, Burk RD, Klein S et al. Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. J. Natl Cancer Inst. 87(18), 1365-1371 (1995).
22. Smith JS, Lindsay L, Hoots B et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int. J. Cancer 121(3), 621-632 (2007). (Pubitemid 46986496)
23. Munoz N, Castellsague X, de Gonzalez AB, Gissmann L. Chapter 1: HPV in the etiology of human cancer. Vaccine 24(Suppl. 3), 1-10 (2006). (Pubitemid 44293019)
24. Mbulawa ZZ, Coetzee D, Marais DJ et al. Genital human papillomavirus prevalence and human papillomavirus concordance in heterosexual couples are positively associated with human immunodeficiency virus coinfection. J. Infect. Dis. 199(10), 1514-1524 (2009).
25. Burchell AN, Winer RL, de Sanjose S, Franco EL. Chapter 6: epidemiology and transmission dynamics of genital HPV infection. Vaccine 24(Suppl. 3), 52-61 (2006).
26. Das BC, Sehgal A, Murthy NS et al. Human papillomavirus and cervical cancer in Indian women. Lancet 2(8674), 1271 (1989). (Pubitemid 19284142)
27. Murthy NS, Sehgal A, Satyanarayana L et al. Risk factors related to biological behaviour of precancerous lesions of the uterine cervix. Br. J. Cancer 61(5), 732-736 (1990). (Pubitemid 20151341)
28. Castellsague X, Bosch FX, Munoz N et al. Male circumcision, penile human papillomavirus infection, and cervical cancer in female partners. N. Engl. J. Med. 346(15), 1105-1112 (2002). (Pubitemid 34984600)
29. Van Howe RS. Human papillomavirus and circumcision: a meta-analysis. J. Infect. 54(5), 490-496 (2007).
30. Tobian AA, Serwadda D, Quinn TC et al. Male circumcision for the prevention of HSV-2 and HPV infections and syphilis. N. Engl. J. Med. 360(13), 1298-1309 (2009).
31. Nandakumar A, Ramnath T, Chaturvedi M. The magnitude of cancer cervix in India. Indian J. Med. Res. 130(3), 219-221 (2009).
32. Bhatla N, Lal N, Bao YP, Ng T, Qiao YL. A meta-analysis of human papillomavirus type-distribution in women from South Asia: implications for vaccination. Vaccine 26(23), 2811-2817 (2008).
33. Das BC, Gopalkrishna V, Das DK et al. Human papillomavirus DNA sequences in adenocarcinoma of the uterine cervix in Indian women. Cancer 72(1), 147-153 (1993). (Pubitemid 23182065)
34. Iwasawa A, Nieminen P, Lehtinen M, Paavonen J. Human papillomavirus DNA in uterine cervix squamous cell carcinoma and adenocarcinoma detected by polymerase chain reaction. Cancer 77(11), 2275-2279 (1996). (Pubitemid 26162420)
35. Das BC, Sharma JK, Gopalakrishna V, Luthra UK. Analysis by polymerase chain reaction of the physical state of human papillomavirus type 16 DNA in cervical preneoplastic and neoplastic lesions. J. Gen. Virol. 73(Pt 9), 2327-2336 (1992).
36. Kailash U, Soundararajan CC, Lakshmy R et al. Telomerase activity as an adjunct to high-risk human papillomavirus types 16 and 18 and cytology screening in cervical cancer. Br. J. Cancer 95(9), 1250-1257 (2006). (Pubitemid 44658491)
37. Pande S, Jain N, Prusty BK et al. Human papillomavirus type 16 variant analysis of E6, E7, and L1 genes and long control region in biopsy samples from cervical cancer patients in north India. J. Clin. Microbiol. 46(3), 1060-1066 (2008). (Pubitemid 351380001)
38. Bhatla N, Dar L, Rajkumar Patro A et al. Human papillomavirus-type distribution in women with and without cervical neoplasia in north India. Int. J. Gynecol. Pathol. 27(3), 426-430 (2008).
39. Bhatla N, Dar L, Patro AR et al. Human papillomavirus type distribution in cervical cancer in Delhi, India. Int. J. Gynecol. Pathol. 25(4), 398-402 (2006). (Pubitemid 44651774)
40. Franceschi S, Rajkumar T, Vaccarella S et al. Human papillomavirus and risk factors for cervical cancer in Chennai, India: a case-control study. Int. J. Cancer 107(1), 127-133 (2003). (Pubitemid 37100096)
41. Sowjanya AP, Jain M, Poli UR et al. Prevalence and distribution of high-risk human papilloma virus (HPV) types in invasive squamous cell carcinoma of the cervix and in normal women in Andhra Pradesh, India. BMC Infect. Dis. 5, 116 (2005). (Pubitemid 43040534)
42. Gopalkrishna V, Hedau S, Kailash U, Das BC. Human papillomavirus type 16 in cancer of the uterine cervix in different geographical regions of India (PS011). Presented at: 18th International Papillomavirus Conference. Barcelona, Spain, 23-28 July 2000.
43. Anwar K, Inuzuka M, Shiraishi T, Nakakuki K. Detection of HPV DNA in neoplastic and non-neoplastic cervical specimens from Pakistan and Japan by non-isotopic in situ hybridization. Int. J. Cancer 47(5), 675-680 (1991).
44. Bhurgri Y. Karachi Cancer Registry Data - implications for the National Cancer Control Program of Pakistan. Asian Pac. J. Cancer Prev. 5(1), 77-82 (2004).
45. Bhurgri Y, Bhurgri A, Rahim A et al. The pattern of malignancies in Karachi (1995 to 1996). J. Pak. Med. Assoc. 49(7), 157-161 (1999).
46. Jamal S, Moghal S, Mamoon N et al. The pattern of malignant tumours: tumour registry data analysis, AFIP, Rawalpindi, Pakistan (1992-2001). J. Pak. Med. Assoc. 56(8), 359-362 (2006). (Pubitemid 44922369)
47. Prusty BK, Kumar A, Arora R, Batra S, Das BC. Human papillomavirus (HPV) DNA detection in self-collected urine. Int. J. Gynaecol. Obstet. 90(3), 223-227 (2005). (Pubitemid 41138921)
48. Laikangbam P, Sengupta S, Bhattacharya P et al. A comparative profile of the prevalence and age distribution of human papillomavirus type 16/18 infections among three states of India with focus on northeast India. Int. J. Gynecol. Cancer 17(1), 107-117 (2007). (Pubitemid 46213978)
49. Franceschi S, Herrero R, Clifford GM et al. Variations in the age-specific curves of human papillomavirus prevalence in women worldwide. Int. J. Cancer 119(11), 2677-2684 (2006). (Pubitemid 44691325)
50. Winer RL, Hughes JP, Feng Q et al. Condom use and the risk of genital human papillomavirus infection in young women. N. Engl. J. Med. 354(25), 2645-2654 (2006). (Pubitemid 43920838)
51. Harper DM, Franco EL, Wheeler C et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 364(9447), 1757-1765 (2004). (Pubitemid 39488060)
52. Villa LL, Costa RL, Petta CA et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre Phase II efficacy trial. Lancet Oncol. 6(5), 271-278 (2005). (Pubitemid 40590263)
53. Markowitz LE, Dunne EF, Saraiya M et al. Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep. 56(RR-2), 1-24 (2007).
54. Garland SM. Can cervical cancer be eradicated by prophylactic HPV vaccination? Challenges to vaccine implementation. Indian J. Med. Res. 130(3), 311-321 (2009).
55. Wheeler CM, Kjaer SK, Sigurdsson K et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. J. Infect. Dis. 199(7), 936-944 (2009).
56. Bayas JM, Costas L, Munoz A. Cervical cancer vaccination indications, efficacy, and side effects. Gynecol. Oncol. 110(3 Suppl. 2), S11-S14 (2008).
57. Arora R, Kumar A, Prusty BK et al. Prevalence of high-risk human papillomavirus (HR-HPV) types 16 and 18 in healthy women with cytologically negative Pap smear. Eur. J. Obstet. Gynecol. Reprod. Biol. 121(1), 104-109 (2005). (Pubitemid 40884647)
58. Munoz N, Manalastas R Jr, Pitisuttithum P et al. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial. Lancet 373(9679), 1949-1957 (2009).
59. AOGIN-INDIA. AOGIN India Biennial Conference (Interim) Proceedings. In: Asia Oceania Research Organization on Genital Infection & Neoplasia (AOGIN). Basu P (Ed.). Kolkata, India (2009).
60. Pillai MR, Hariharan R, Babu JM et al. Molecular variants of HPV-16 associated with cervical cancer in Indian population. Int. J. Cancer 125(1), 91-103 (2009).
61. WHO. Global Human Papillomavirus (HPV) Laboratory Network. In: WHO HPV LabNet - Newsletter 01. WHO, Geneva, Switzerland (2007).
62. Lower Genital Tract Precancer. Colposcopy, Pathology and Treatment. Singer A, Monaghan JM (Eds). Blackwell, Oxford, UK (2000).
63. Sankaranarayanan R, Nene BM, Shastri SS et al. HPV screening for cervical cancer in rural India. N. Engl. J. Med. 360(14), 1385-1394 (2009).
64. Qiao YL, Sellors JW, Eder PS et al. A new HPV-DNA test for cervical-cancer screening in developing regions: a cross-sectional study of clinical accuracy in rural China. Lancet Oncol. 9(10), 929-936 (2008).
65. Moore KN, Walker JL. High risk human papillomavirus testing: guidelines for use in screening, triage, and follow-up for the prevention and early detection of cervical cancer. J. Natl Compr. Canc. Netw. 2(6), 589-596 (2004).
66. Manos MM, Kinney WK, Hurley LB et al. Identifying women with cervical neoplasia: using human papillomavirus DNA testing for equivocal Papanicolaou results. JAMA 281(17), 1605-1610 (1999).
67. Ronnett BM, Manos MM, Ransley JE et al. Atypical glandular cells of undetermined significance (AGUS): cytopathologic features, histopathologic results, and human papillomavirus DNA detection. Hum. Pathol. 30(7), 816-825 (1999).
68. Hubbard RA. Human papillomavirus testing methods. Arch. Pathol. Lab. Med. 127(8), 940-945 (2003).
69. Chen B, Yin H, Dhurandhar N. Detection of human papillomavirus DNA in esophageal squamous cell carcinomas by the polymerase chain reaction using general consensus primers. Hum. Pathol. 25(9), 920-923 (1994). (Pubitemid 24292409)
70. Monk BJ, Cook N, Ahn C et al. Comparison of the polymerase chain reaction and Southern blot analysis in detecting and typing human papilloma virus deoxyribonucleic acid in tumors of the lower female genital tract. Diagn. Mol. Pathol. 3(4), 283-291 (1994). (Pubitemid 24378945)
71. Saiki RK, Walsh PS, Levenson CH, Erlich HA. Genetic analysis of amplified DNA with immobilized sequence-specific oligonucleotide probes. Proc. Natl Acad. Sci. USA 86(16), 6230-6234 (1989).
72. Schiffman MH, Bauer HM, Lorincz AT et al. Comparison of Southern blot hybridization and polymerase chain reaction methods for the detection of human papillomavirus DNA. J. Clin. Microbiol. 29(3), 573-577 (1991).
73. Laconi S, Greco M, Pellegrini-Bettoli P et al. One-step detection and genotyping of human papillomavirus in cervical samples by reverse hybridization. Diagn. Mol. Pathol. 10(3), 200-206 (2001). (Pubitemid 32808115)
74. Reesink-Peters N, Burger MP, Kleter B et al. Using a new HPV detection system in epidemiological research: change of views on cervical dyskaryosis? Eur. J. Obstet. Gynecol. Reprod. Biol. 98(2), 199-204 (2001). (Pubitemid 33713892)
75. Manos MM, Waldman J, Zhang TY et al. Epidemiology and partial nucleotide sequence of four novel genital human papillomaviruses. J. Infect. Dis. 170(5), 1096-1099 (1994). (Pubitemid 24328610)
76. Perrons C, Kleter B, Jelley R et al. Detection and genotyping of human papillomavirus DNA by SPF10 and MY09/11 primers in cervical cells taken from women attending a colposcopy clinic. J. Med. Virol. 67(2), 246-252 (2002). (Pubitemid 34493439)
77. Coutlee F, Gravitt P, Kornegay J et al. Use of PGMY primers in L1 consensus PCR improves detection of human papillomavirus DNA in genital samples. J. Clin. Microbiol. 40(3), 902-907 (2002). (Pubitemid 34208642)
78. Gravitt PE, Peyton CL, Alessi TQ et al. Improved amplification of genital human papillomaviruses. J. Clin. Microbiol. 38(1), 357-361 (2000).
79. Das BC, Sharma JK, Gopalkrishna V et al. A high frequency of human papillomavirus DNA sequences in cervical carcinomas of Indian women as revealed by Southern blot hybridization and polymerase chain reaction. J. Med. Virol. 36(4), 239-245 (1992).
80. Durst M, Gissmann L, Ikenberg H, zur Hausen H. A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions. Proc. Natl Acad. Sci. USA 80(12), 3812-3815 (1983). (Pubitemid 13063146)
81. Hallam N, Gibson P, Green J, Charnock M. Detection and typing of human papillomavirus infection of the uterine cervix by dot blot hybridisation: comparison of scrapes and biopsies. J. Med. Virol. 27(4), 317-321 (1989). (Pubitemid 19125788)
82. Moberg M, Gustavsson I, Gyllensten U. Real-time PCR-based system for simultaneous quantification of human papillomavirus types associated with high risk of cervical cancer. J. Clin. Microbiol. 41(7), 3221-3228 (2003). (Pubitemid 36842325)
83. Feng Q, Cherne S, Winer RL et al. Development and evaluation of a liquid bead microarray assay for genotyping genital human papillomaviruses. J. Clin. Microbiol. 47(3), 547-553 (2009).
84. Schmitt M, Bravo IG, Snijders PJ et al. Bead-based multiplex genotyping of human papillomaviruses. J. Clin. Microbiol. 44(2), 504-512 (2006). (Pubitemid 43222244)
85. Kailash U, Hedau S, Gopalkrishna V, Katiyar S, Das BC. A simple 'paper smear' method for dry collection, transport and storage of cervical cytological specimens for rapid screening of HPV infection by PCR. J. Med. Microbiol. 51(7), 606-610 (2002). (Pubitemid 34747992)
86. Das BC, Gopalkrishna V, Sharma JK, Roy M, Luthra UK. Human papillomavirus DNA in urine of women with preneoplastic and neoplastic cervical lesions. Lancet 340(8832), 1417-1418 (1992).
87. Gupta A, Arora R, Gupta S et al. Human papillomavirus DNA in urine samples of women with or without cervical cancer and their male partners compared with simultaneously collected cervical/penile smear or biopsy specimens. J. Clin. Virol. 37(3), 190-194 (2006). (Pubitemid 44548476)
88. Wilkinson DE, Baylis SA, Padley D et al. Establishment of the 1st World Health Organization international standards for human papillomavirus type 16 DNA and type 18 DNA. Int. J. Cancer 126(12), 2969-2983 (2009) .
89. Shukla S, Bharti AC, Hussain S et al. Elimination of high-risk human papillomavirus type HPV16 infection by 'Praneem' polyherbal tablet in women with early cervical intraepithelial lesions. J. Cancer Res. Clin. Oncol. 135(12), 1701-1709 (2009).
90. Prusty BK, Das BC. Constitutive activation of transcription factor AP-1 in cervical cancer and suppression of human papillomavirus (HPV) transcription and AP-1 activity in HeLa cells by curcumin. Int. J. Cancer 113(6), 951-960 (2005).
91. Mahata S. Transcriptional control of human papillomavirus oncogene expression by antioxidative agents. In: PhD thesis, Department of Biosciences. Jamia Millia Islamia, New Delhi, India, 190 (2009).
92. Goldie SJ, Gaffikin L, Goldhaber-Fiebert JD et al. Cost-effectiveness of cervical-cancer screening in five developing countries. N. Engl. J. Med. 353(20), 2158-2168 (2005). (Pubitemid 41653107)